Categories: NewsNutrition

Theralogix Launches Mannose One for Next-Level Urinary Tract Protection

ROCKVILLE, MD / ACCESSWIRE / January 8, 2024 / Theralogix, a national leader in the nutritional supplement industry, proudly announces Mannose One, the only independently tested and content-certified d-mannose supplement.

Theralogix recognized the need for evidence-based, quality-assured solutions for urinary tract concerns. Mannose One provides a proactive and reliable defense.

D-mannose is a naturally occurring compound that helps prevent the adherence of bacteria to the bladder lining. Each serving of Mannose One provides 2,000 mg of d-mannose, the daily dose shown by research to flush bacteria from the urinary tract. Mannose One is proudly manufactured in the USA in a GMP-compliant facility and is dye-free, gluten-free, and vegan-friendly.

Mannose One goes hand-in-hand with Theralogix’s leading product, TheraCran One. With 500 mg of cranberry extract and at least 36 mg of soluble proanthocyanidins (PACs) per capsule, TheraCran One is the only independently certified cranberry supplement formulated to prevent UTIs.** Both the cranberry PACs in TheraCran One and the d-mannose in Mannose One prevent bacteria from sticking to the bladder lining. Since each compound has its own unique mechanism of action, there is a benefit to taking both for optimal urinary tract health.*

Like all Theralogix products, Mannose One is independently tested and content-certified by NSF International, the highest standard for purity and content accuracy. This third-party certification guarantees that each product contains exactly what the label says – nothing more and nothing less.

Theralogix raises the bar when it comes to premium, research-backed nutritional supplements. Every product is independently certified by NSF® International for content accuracy and freedom from contaminants. Theralogix has been a top physician-recommended brand for over two decades. Mannose One is now available on the Theralogix website and Amazon.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

**Limited scientific evidence shows that by consuming 500 mg each day of cranberry dietary supplement, healthy women who have had a urinary tract infection (UTI) may reduce their risk of recurrent UTI.

Contact Information

Shannon Mahon
smahon@theralogix.com
301.464.7210

SOURCE: Theralogix

View the original press release on newswire.com.

Staff

Recent Posts

TODAY SHOW EXPOSES AI MEDICAL SCAMS TARGETING LIPEDEMA PATIENTS

LOS ANGELES, Dec. 5, 2025 /PRNewswire/ -- AI-generated deepfake scams are rapidly spreading across social media,…

4 hours ago

Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc.

Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / December 5, 2025…

7 hours ago

Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc.

Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, BC / ACCESS Newswire / December 5, 2025…

7 hours ago

Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement

Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink:…

10 hours ago

Techficient Launches Surefire, Its Proprietary Modern Underwriting Engine

BOISE, Idaho, Dec. 5, 2025 /PRNewswire/ -- Techficient, a leading innovator in Insurtech solutions, announces the…

10 hours ago

Clinical Education Alliance Becomes Decera Clinical, Delivering Education, Insights, and Communications

Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON,…

10 hours ago